Program

June 11, 2009
8:00 Registration
8:40 Gios Bernardi welcomed Focus & Goals
9:00 Sean Morrison Focus & Goals: Tumorigenic potential is a common attribute in some cancers

AM, Session I – Metabolic Pathways as Targets
Moderator: S. Elmore
9:50 Bruce Spiegelman Discussion: Transcriptional control of energy homeostasis
10:15 William Kaelin Discussion: 2-oxoglutarate-dependent dioxygenases as therapeutic targets in cancer
11:35 Poster Session & Lunch

PM, Session II – Cell Death Interference
Moderator: G. Superti-Furga
13:00 Vishva Dixit Discussion: Deubiquitinases as therapeutic targets in cancer
13:25 Gregor Verdone Discussion: Forget everything you ever heard about “undruggable” targets
13:45 Nika Danial Discussion: Deubiquitinases as therapeutic targets in cancer
14:00 Coffee break
15:45 Nika Danial Discussion: Integration of glucose metabolism and apoptosis
15:45 Steven Elmore Discussion: Allowing sick cells to die: Targeting Bcl-2 family proteins to treat cancer
16:35 Wilhelm Krek Discussion: VHL: Linking microtubules to primary cilia maintenance, chromosome stability and tumor suppression
17:25 Adjourn

June 12, 2009
8:30 Emilio Hirsch Discussion: Genetic modeling of PI3K inhibition
8:45 David Sabatini Discussion: The therapeutic potential of the mTOR pathway
9:00 Sean Morrison – Keynote Address: Tumorigenic potential is a common attribute in some cancers

AM, Session III – Unexpected Outcomes of Targeting Signal Transduction Proteins
Moderator: P. Finan
8:30 Emilio Hirsch Discussion: Genetic modeling of PI3K inhibition
9:00 David Sabatini Discussion: The therapeutic potential of the mTOR pathway
10:10 Coffee break
10:25 Thomas Roberts Discussion: What lies beyond the first round of PI3 kinases inhibitors?
11:15 Poster Session & Lunch

PM, Session IV – New Approaches to Target Finding
Moderator: E. Hirsch
13:00 Giulio Superti-Furga Discussion: Molecular networks and chemical proteomics: charting drug targets
13:25 Peter Finan Discussion: Dissecting pathways by chemical genetics
14:00 William Hahn Discussion: Functional genomic approaches to identify cancer targets and co-dependencies
15:30 Coffee break
15:45 Inder Verma Discussion: Mouse tumors using lentiviral vectors
16:10 Todd Golub Discussion: Genomic approaches to drug discovery
17:25 Adjourn
20:00 Symposium Dinner

June 13, 2009
8:00 Best Posters’ Oral Presentations
9:00 Pier Paolo Pandolfi Discussion: Targeting the cancer initiating cell for therapy
9:45 Charles Sawyer Discussion: Rethinking 24/7 target inhibition
10:40 Coffee break
10:50 Zaver Bhujwalla Discussion: Conventional imaging to guide therapy of unconventional targets
11:35 Robert Kerbel Discussion: Some unexpected outcomes of therapeutically interfering with VEGF pathway function
12:30 Adjourn

AM, Session V – Clinical Translation
Moderator: W. Kaelin
8:00 Best Posters’ Oral Presentations
9:00 Pier Paolo Pandolfi Discussion: Targeting the cancer initiating cell for therapy
9:45 Charles Sawyer Discussion: Rethinking 24/7 target inhibition
10:40 Coffee break
10:50 Zaver Bhujwalla Discussion: Conventional imaging to guide therapy of unconventional targets
11:35 Robert Kerbel Discussion: Some unexpected outcomes of therapeutically interfering with VEGF pathway function
12:30 Adjourn
20:00 Symposium Dinner

Invited Participants
– Zaver Bhujwalla
  Johns Hopkins Univ, Baltimore, MD
– Nika Danial
  Dana Farber Cancer Inst, Boston, MA
– Vishva Dixit
  Genentech, San Francisco, CA
– Steven Elmore
  Abbott Laboratories, Abbott Park, IL
– Peter Finan
  Novartis Inst for Biomedical Res, Cambridge, MA
– Todd Golub
  Dana Farber Cancer Inst, Boston, MA
– William Hahn
  Dana Farber Cancer Inst, Boston, MA
– Emilio Hirsch
  Univ of Torino, Torino, Italy
– William Kaelin
  Dana Farber Cancer Inst, Boston, MA
– Robert Kerbel
  Univ of Toronto, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
– Wilhelm Krek
  Inst of Cell Biology, Zurich, Switzerland
– David Livingston
  Dana Farber Cancer Inst, Boston, MA
– Enrico Milich
  Roswell Park Cancer Inst, Buffalo NY
– Sean Morrison
  Univ of Michigan Ctr for Stem Cell Biol, Ann Arbor, MI
The Pezcoller Foundation

The Pezcoller Foundation is a non-profit organisation created in 1980 by Prof. Alessio Pezcoller (1896 - 1993), Chief Surgeon of Santa Chiara Hospital of Trento, Italy. The goal of the Foundation is to promote biomedical research.

Activities:

- PEZCOLLER FOUNDATION-AACR INTERNATIONAL AWARD FOR CANCER RESEARCH – 75,000 Euro: this prize is presented, every year, to a scientist who has made a major scientific discovery in the field of cancer.
- PEZCOLLER FOUNDATION-ECCO RECOGNITION FOR CONTRIBUTION TO ONCOLOGY – 30,000 Euro: this prize is presented, every two years to a single individual (scientist, clinician, nurse etc.) for his/her professional life dedication to the improvement of cancer treatment, care and research.
- THE PEZCOLLER SYMPOSIUM: a series of annual symposia promoting interactions among scientists working at the cutting edge of basic oncological sciences.
- PEZCOLLER SEMINARS: a series of educational meetings for Medical Doctors.
- PEZCOLLER FOUNDATION FELLOWSHIP: for professional updating in oncology.
- THE PEZCOLLER FOUNDATION JOURNAL: this periodical is published in order to provide a direct link, at six monthly intervals, between the Pezcoller Foundation and the international medical and scientific community.

This Symposium is supported by

- Fondazione Cassa di Risparmio di Trento e Rovereto
- Provincia autonoma di Trento
- Comune di Trento
- Comune di Rovereto

The focus of the Symposium will be on identifying new targets for anticancer drugs action, and on utilizing new concepts and methods for drug design and development. The topics to be discussed will include protein/protein interactions, targeting transcription factors, targeting death pathways, new chemical screening of novel molecular targets, valid alternatives to known target proteins, and unexpected effects of disrupted angiogenesis. Each talk will be followed by an equal time for discussion thus providing ample opportunities for interactions and cross-fertilization among participants.

A session of posters in the areas discussed at the Symposium will be included. Poster abstracts should be submitted to Enrico Mihich (Roswell Park Cancer Institute, Buffalo, NY; enrico.mihich@roswellpark.org) on or before May 15, 2009 and will be reviewed for acceptance by the Co-chairmen. For scientific matters contact Dr. Mihich (enrico.mihich@roswellpark.org) or Dr. Livingston (david_livingston@dfci.harvard.edu). For local arrangements and travel matters contact Pezcoller Foundation secretariat office, Trento, Italy, Pezcoller@pezcoller.it.